Lillys Mirikizumab Met Primary Endpoint and Key Secondary Endpoints in Phase 2 Study in Patients with Crohns Disease

INDIANAPOLISÂMay 21 2019ÂPRNewswire &8212; In an oral presentation from the Digestive Disease Week medical conference inÂSan Diego CaliforniaÂtodayÂEliÂLilly and CompanyNYSE LLY announced new safety and efficacy data for mirikizumab in patients with mo...